MolDX: Melanoma Risk Stratification Molecular Testing (L37750) Final LCD - Effective August 08, 2022

This Local Coverage Determination (LCD) has completed the Open Public Meeting and is now finalized under contractor numbers: 01112 (NCA), 01182 (SCA), 01212 (AS, GU, HI, NMI), and 01312 (NV). Responses to comments received may be found as a link at the bottom of the final LCD.

Medicare Coverage Database (MCD) Number/Contractor Determination Number: L37750

LCD Title: MolDX: Melanoma Risk Stratification Molecular Testing

Effective Date: August 08, 2022

Summary of LCD: This policy describes and clarifies coverage for molecular diagnostic tests used to assist in risk stratification of melanoma patients.

Visit the Proposed LCDs webpage to access this LCD.

 

Last Updated Jun 22 , 2022